Search Results - "Decristoforo, C."

Refine Results
  1. 1
  2. 2

    On-cartridge preparation and evaluation of 68Ga-, 89Zr- and 64Cu-precursors for cell radiolabelling by Socan, A., Petrik, M., Kolenc Peitl, P., Krošelj, M., Rangger, C., Novy, Z., Svajger, U., Gmeiner, T., Decristoforo, C.

    Published in Nuclear medicine and biology (01-04-2019)
    “…Indium-111 when formulated as indium-111 oxine remains the gold standard for long term cell tracking, whereas radiometals for improved PET applications still…”
    Get full text
    Journal Article
  3. 3

    Molecular Imaging: In Vivo Agents for the Diagnosis and Treatment of Cancer by Haeusler, D., Decristoforo, C., Frost, J., Gobalakrishnan, S., Huang, Y. Y.

    Published in Contrast media and molecular imaging (01-01-2018)
    “…The topics cover the development of molecular imaging agents targeting the cholecystokinin 2 receptor (CCK2R), the adenosine A3 receptor (A3R), and the human…”
    Get full text
    Journal Article
  4. 4

    Radiopharmaceuticals are special, but is this recognized? The possible impact of the new Clinical Trials Regulation on the preparation of radiopharmaceuticals by Decristoforo, C., Penuelas, I., Elsinga, P., Ballinger, J., Winhorst, A. D., Verbruggen, A., Verzijlbergen, F., Chiti, A.

    “…Nuclear medicine techniques are in the forefront of molecular imaging, thereby translating discoveries in molecular biology, genetics, pharmacology and many…”
    Get full text
    Journal Article
  5. 5

    Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals by Koziorowski, J., Behe, M., Decristoforo, C., Ballinger, J., Elsinga, P., Ferrari, V., Kolenc Peitl, P., Todde, S., Mindt, T. L.

    Published in EJNMMI radiopharmacy and chemistry (21-03-2016)
    “…This is a position paper of the Radiopharmacy Committee of the EANM (European Association of Nuclear Medicine) addressing toxicology studies for application of…”
    Get full text
    Journal Article
  6. 6

    Full automation of (68)Ga labelling of DOTA-peptides including cation exchange prepurification by Ocak, M, Antretter, M, Knopp, R, Kunkel, F, Petrik, M, Bergisadi, N, Decristoforo, C

    Published in Applied radiation and isotopes (01-02-2010)
    “…Here we describe a fully automated approach for the synthesis of (68)Ga-labelled DOTA-peptides based on pre-concentration and purification of the generator…”
    Get full text
    Journal Article
  7. 7

    Towards a harmonized radiopharmaceutical regulatory framework in Europe? by Decristoforo, A, Peñuelas, I

    “…Despite European unification regarding a common legal framework for many aspects of pharmaceutical production including industrial manufacture of…”
    Get full text
    Journal Article
  8. 8

    Expression of somatostatin receptor subtype 2 and subtype 5 in thyroid malignancies by Woelfl, S, Bogner, S, Huber, H, Salaheddin-Nassr, S, Hatzl, M, Decristoforo, C, Virgolini, I, Gabriel, M

    Published in Nuklearmedizin. Nuclear medicine (01-01-2014)
    “…To retrospectively analyse the expression of somatostatin receptor subtypes 2 (SSTR 2) and 5 (SSTR 5) in thyroid malignancies, possibly the most relevant…”
    Get more information
    Journal Article
  9. 9

    Evidence for Somatostatin receptor 2 in thyroid tissue by Druckenthaner, M., Schwarzer, C., Ensinger, C., Gabriel, M., Prommegger, R., Riccabona, G., Decristoforo, C.

    Published in Regulatory peptides (10-01-2007)
    “…Somatostatin receptor scintigraphy has found considerable interest for imaging thyroid tumours. Recently, also therapeutic application of Somatostatin…”
    Get full text
    Journal Article
  10. 10

    68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT by Kroiss, A., Putzer, D., Decristoforo, C., Uprimny, C., Warwitz, B., Nilica, B., Gabriel, M., Kendler, D., Waitz, D., Widmann, G., Virgolini, I. J.

    “…Purpose We wanted to establish the range of 68 Ga-DOTA-TOC uptake in liver and bone metastases of patients with neuroendocrine tumours (NET) and to establish…”
    Get full text
    Journal Article
  11. 11

    Comparison of in vitro and in vivo properties of [99mTc]cRGD peptides labeled using different novel Tc-cores by Decristoforo, C, Santos, I, Pietzsch, H J, Kuenstler, J U, Duatti, A, Smith, C J, Rey, A, Alberto, R, Von Guggenberg, E, Haubner, R

    “…The alfa(v)beta(3) integrin is involved in angiogenesis and tumor metastasis. Arginine-glycine-aspartic acid (RGD)-peptides bind with high affinity to this…”
    Get full text
    Journal Article
  12. 12

    Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence by Decristoforo, C, Mather, S J

    Published in European journal of nuclear medicine (01-08-1999)
    “…In this paper the preclinical evaluation of the somatostatin analogue RC160 labelled with technetium-99m using bifunctional chelators (BFCs) based on the…”
    Get full text
    Journal Article
  13. 13
  14. 14

    99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours by von Guggenberg, E, Dietrich, H, Skvortsova, I, Gabriel, M, Virgolini, I J, Decristoforo, C

    “…Different attempts have been made to develop a suitable radioligand for targeting CCK-2 receptors in vivo, for staging of medullary thyroid carcinoma (MTC) and…”
    Get full text
    Journal Article
  15. 15

    99mTc-Labeling and in Vitro and in Vivo Evaluation of HYNIC- and (Nα-His)Acetic Acid-Modified [d-Glu1]-Minigastrin by von Guggenberg, E, Behe, M, Behr, T. M, Saurer, M, Seppi, T, Decristoforo, C

    Published in Bioconjugate chemistry (01-07-2004)
    “…Gastrin/CCK-2 receptors are overexpressed in a number of tumors such as medullary thyroid cancer (MTC) and small cell lung cancer (SCLC). Recently…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20